FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL										
ОМВ	Number:	3235-0287									
Estin	nated average b	ourden									

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

				-												
Name and Address of Reporting Person* A COLUMN TO A COLUMN T					2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC [alxn]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
KEISER DAVID W			1-							X Directo	or		10% Ow	ner		
(Last)	(Last) (First) (Middle)				3. Date of Earliest Transaction (Month/Day/Year) 09/23/2003					_ .	X Officer below)	(give title		Other (s below)	pecify	
C/O ALEXION PHARMACEUTICALS INC											Presid	President & Chief Operating Of			f	
352 KN0	OTTER DR	IVE		0	JI 2 JI 2	.003										
					4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable					
(Street)											Line	*	iled by One	Dane	orting Persor	
CHESH	RE C	Γ	06410										•		orung Persor One Repor	
												Persoi		e iliai	гоне керог	urig
(City)	(S	tate)	(Zip)													
		Tak	le I - Non-E	Derivativ	⁄e Se	curities	s Ac	quired, D	isposed	of, or Be	neficial	ly Owned	I			
1. Title of	Security (Inst	tr. 3)		. Transactio						5. Amou				7. Nature		
Date (Month/Da			ate Month/Day/\	Execution Date, if any (Month/Day/Year)		Code (Instr. 5)		tr. 3, 4 and	Benefici	Beneficially (D) o Owned Following (I) (Ir Reported		or Indirect Instr. 4)	Beneficial Ownership (Instr. 4)			
								_								
						Code V	Amoun	t (A) oi (D)	Price	Transac (Instr. 3	and 4)	on(s) nd 4)				
		-	Table II - De	erivative	Sec	urities	Acai	uired. Dis	nosed o	f. or Ben	eficially	Owned			<u> </u>	
								, options								
1. Title of	2.	3. Transaction	3A. Deemed	4.		5. Numb	oer	6. Date Exer			d Amount	8. Price of	9. Numbe		10.	11. Nature
Derivative Security	Conversion or Exercise	(Month/Day/Year) if a	Execution Date, if any	Code	action (Instr.	r. Derivative		Expiration D (Month/Day/		of Securit Underlyin	g	Derivative Security	derivative Securities		Ownership Form:	Beneficial
(Instr. 3) Price of (Month/Da			(Month/Day/Ye	ear) 8)		Securities Acquired		Derivative Secu (Instr. 3 and 4)				(Instr. 5)	Beneficially Owned		Direct (D) or Indirect	Ownership (Instr. 4)
	Security (A) or Disposed						•		Following Reported		(I) (Instr. 4)					
					of (D) (Instr. 3, 4 and 5)							Transaction(s) (Instr. 4)				
			1						Amount	1	<u> </u>					
											or Number					
				Code	\v	(A)	(D)	Date Exercisable	Expiration Date	Title	of Shares					
Option to						\										
purchase Common										Common Stock.						
Stock, par	\$17.67	09/23/2003		Α		12,000		(1)	09/23/201	par value	12,000	\$0	12,000	0	D	
value \$.0001 per										\$.0001 per share						
hare	1	I	ı	1	1	1			1	1	1	I	1			I

Explanation of Responses:

1. 1/16th vests every 3 months following transaction date.

Thomas I.H. Dubin

11/13/2003

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.